Reticular Bullous Epithelial Corneal Edema after Netarsudil Use for Elevated Intraocular Pressure with Concurrent Fuchs Endothelial Corneal Dystrophy: A Case Report.

Autor: Park KS; Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, CA, USA., Lieu AC; Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, CA, USA., Ang MJ; Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, CA, USA., Afshari NA; Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, CA, USA.
Jazyk: angličtina
Zdroj: Case reports in ophthalmology [Case Rep Ophthalmol] 2024 Apr 17; Vol. 15 (1), pp. 369-373. Date of Electronic Publication: 2024 Apr 17 (Print Publication: 2024).
DOI: 10.1159/000538119
Abstrakt: Introduction: We describe a case of reticular bullous corneal epithelial edema associated with the use of netarsudil ophthalmic solution (0.02%) for elevated intraocular pressure.
Case Presentation: A 74-year-old man with a complex ocular medical history, including Fuchs dystrophy and primary open-angle glaucoma, developed progressively worsening loss of vision 3 weeks following the initiation of topical netarsudil for increased intraocular pressure. Visual acuity in the left eye was counting fingers at 3 feet and intraocular pressure in the left eye was 7 mm Hg. A characteristic "honeycomb" pattern epitheliopathy was seen on ocular examination.
Conclusion: Reticular bullous epithelial corneal edema is an uncommon finding associated with netarsudil use, which can be overlooked in favor of corneal edema associated with Fuchs dystrophy. This is especially relevant given Fuchs dystrophy itself is a predisposing risk factor for netarsudil-induced reticular bullous corneal epithelial edema. Improvement of both the corneal edema and visual acuity should be expected after discontinuing netarsudil and undergoing superficial keratectomy.
Competing Interests: Natalie A. Afshari has no relevant financial disclosures. She is a consultant to the following companies not related to this submitted work: Trefoil Therapeutics, GSK, Dompe, Claris Biotherapeutics, Alpine Biotherapeutics, and Aescula Tech. The remaining authors have no financial disclosures.
(© 2024 The Author(s). Published by S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje